Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly’s Solanezumab Fails, But The Surprise Would Have Been Success

Executive Summary

The Phase III failure of the Alzheimer’s treatment was largely expected, but is nonetheless a disappointment for the disease and for the anti-amyloid field, casting a shadow over other therapies in development, including Lilly’s own pipeline.


Related Content

Eisai Opts In On Biogen's High-Profile Aducanumab
Finance Watch: Lilly Cuts 3,500 Jobs Globally To Drive Growth
FDA Should Let Alzheimer’s Trials Rely On Single Endpoint, Group Says
Looser Efficacy Standards Could Waste Taxpayer Dollars On Useless Drugs, NEJM Says
Accera Posts Phase III Alzheimer's Failure, But Moves Ahead With New Formulation
Another Nail In Amyloid Hypothesis Coffin? Merck Ends Pivotal BACE Inhibitor Study
Can New Drugs Meet Lilly’s Revenue Goals If Solanezumab Fails?
Lilly's Leap Tests Investors' Faith In Solanezumab
Lilly Poised To Lead In Alzheimer’s, But Success Depends On Solanezumab
Efficacy Signal For Lilly’s Solanezumab Stirs The Alzheimer’s Pot


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts